Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-025019
Filing Date
2025-02-21
Accepted
2025-02-21 17:54:34
Documents
2
Period of Report
2025-02-19

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1549
2 EX-24.1 howl-ex24_1.htm EX-24.1 14725
  Complete submission text file 0000950170-25-025019.txt   17744
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Issuer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O TRISALUS LIFE SCIENCES, INC. 6272 W. 91ST AVENUE WESTMINSTER CO 80031
Business Address
Singhal Anil K. (Reporting) CIK: 0001982984 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40366 | Film No.: 25653487